Looking Into Vivos Therapeutics's Return On Capital Employed - Vivos Therapeutics (NASDAQ:VVOS)
Benzinga According to data from Benzinga Pro, during Q1, Vivos Therapeutics's VVOS reported sales totaled $3.86 million. Despite a 72.03% increase in earnings, the company posted a loss of $1.70 million. In Q4, Vivos Therapeutics brought in $3.95 million in sales but lost $6.09 million in earnings.
What Is ROCE?
Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q1, Vivos Therapeutics posted an ROCE of -0.24%.
It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but does not account for factors that could affect earnings and sales in the near future.
ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Vivos Therapeutics is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.
